MedicaidPrior AuthMedium impact
Lunsumio® & Lunsumio Velo™ (mosunetuzumab-axgb) (Revised)
Humana·LA · Oncology, Hematology·Medicaid
Effective date
May 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicaid Louisiana has established new prior authorization requirements for Lunsumio and Lunsumio Velo (mosunetuzumab-axgb) for treating relapsed/refractory follicular lymphoma. Prior authorization is required with specific criteria including diagnosis confirmation, at least two prior systemic therapies, and monotherapy use.
Action Required
Before May 1, 2026: Billing and clinical teams must implement prior authorization requirements for Lunsumio and Lunsumio Velo prescriptions. Update systems to verify patient meets all four criteria: follicular lymphoma diagnosis, relapsed/refractory disease, received at least two prior systemic therapies, and using as monotherapy. Obtain prior authorization before administration or claims will be denied. Initial approvals valid for 6 months with 6-month renewals available.